An Open Label Phase I Dose Escalation Study of E7080 Administered to Patients With Solid Tumors
Status:
Completed
Trial end date:
2008-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the maximum tolerable dose (MTD) and the related
effects of E7080 administered to patients with solid tumors that are resistant to approved
existing anti-tumor therapies, or for which no appropriate treatment is available.